Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study
Titel:
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study
Auteur:
Montalban, Xavier Arnold, Douglas L Weber, Martin S Staikov, Ivan Piasecka-Stryczynska, Karolina Martin, Emily C Syed, Sana Dangond, Fernando Wolinsky, Jerry S